Technology ID
E-326-2013-0

Novel Live-Attenuated Rabies Vaccine

Linked ID
TAB-2649
Inventors
Charles Rupprecht (CDC)
Xianfu Wu (CDC)
Lead Inventors
Xianfu Wu (CDC)
Co-Inventors
Charles Rupprecht (CDC)
Development Status
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • Rabies vaccine design and development
  • Immunogenic compositions for both prevention and treatment of rabies virus
  • Rabies virus research
The critical feature of this technology is the Evelyn-Rokitnicki-Abelseth (ERA) rabies whole genome DNA sequence. With the availability of the entire rabies genome, a recombinant vaccine can be developed using reverse genetics. Using this technology, CDC researchers have developed a recombinant, live-attenuated vaccine shown to confer protection against lethal doses of live, street-rabies virus in multiple survival studies. This vaccine offers better protection than traditional inactivated vaccinations, as demonstrated in co-infection studies. Further, a single intramuscular vaccination with the CDC's attenuated-virus was sufficient for survival of 100% of hamsters and mice following lethal challenge.
Competitive Advantages
  • Live attenuated vaccine shows greater efficacy than older inactivated vaccine
  • 100% animal survival conferred by a single inoculation before lethal challenge

Request More Info

Licensing Contact